Home / Lifestyle / Health & Fitness / Article /
Drug trial shows hope for less invasive treatment of rare foetal blood disease
Updated On: 08 August, 2024 04:05 PM IST | Mumbai | IANS
Currently, treatment typically involves multiple ultrasound-guided intrauterine blood transfusions, which carry risks like fetal death, premature rupture of membranes, and pre-term birth
Listen to this article :
Image for representational purposes only. Photo Courtesy: iStock
A new investigational drug, nipocalimab, has shown promising results in altering the standard treatment for Hemolytic Disease of the Fetus and Newborn (HDFN), potentially delaying or preventing anemia and reducing the need for intrauterine blood transfusions in high-risk pregnancies.
HDFN is a severe condition where the blood types of a mother and her foetus are incompatible, leading to life-threatening anemia in the baby.
Trending Stories
Latest Photos
Latest Videos
Latest Web Stories
ADVERTISEMENT
Mid-Day Fast
ADVERTISEMENT
ADVERTISEMENT